Systematic investigation of metabolic reprogramming in different cancers based on tissue-specific metabolic models

Cancer cells have different metabolism in contrast to normal cells. The advancement in omics measurement technology enables the genome-wide characterization of altered cellular processes in cancers, but the metabolic flux landscape of cancer is still far from understood. In this study, we compared the well-reconstructed tissue-specific models of five cancers, including breast, liver, lung, renal, and urothelial cancer, and their corresponding normal cells. There are similar patterns in majority of significantly regulated pathways and enriched pathways in correlated reaction sets. But the differences among cancers are also explicit. The renal cancer demonstrates more dramatic difference with other cancer models, including the smallest number of reactions, flux distribution patterns, and specifically correlated pathways. We also validated the predicted essential genes and revealed the Warburg effect by in silico simulation in renal cancer, which are consistent with the measurements for renal cancer. In conclusion, the tissue-specific metabolic model is more suitable to investigate the cancer metabolism. The similarity and heterogenicity of metabolic reprogramming in different cancers are crucial for understanding the aberrant mechanisms of cancer proliferation, which is fundamental for identifying drug targets and biomarkers.

[1]  A. Mardinoğlu,et al.  Systems medicine and metabolic modelling , 2012, Journal of internal medicine.

[2]  Robert V Farese,et al.  Cellular fatty acid metabolism and cancer. , 2013, Cell metabolism.

[3]  Natapol Pornputtapong,et al.  Reconstruction of Genome-Scale Active Metabolic Networks for 69 Human Cell Types and 16 Cancer Types Using INIT , 2012, PLoS Comput. Biol..

[4]  Gabriela Kalna,et al.  Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase , 2011, Nature.

[5]  F. Pontén,et al.  The Human Protein Atlas—a tool for pathology , 2008, The Journal of pathology.

[6]  Cristina Bianchi,et al.  Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. , 2015, Cancer research.

[7]  Z. Oltvai,et al.  Molecular Crowding Defines a Common Origin for the Warburg Effect in Proliferating Cells and the Lactate Threshold in Muscle Physiology , 2011, PloS one.

[8]  Jens Nielsen,et al.  Flux balance analysis predicts essential genes in clear cell renal cell carcinoma metabolism , 2015, Scientific Reports.

[9]  V. Mootha,et al.  Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation , 2012, Science.

[10]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[11]  B. Matthews Comparison of the predicted and observed secondary structure of T4 phage lysozyme. , 1975, Biochimica et biophysica acta.

[12]  I. Nookaew,et al.  Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma , 2014, Proceedings of the National Academy of Sciences.

[13]  Giancarlo Mauri,et al.  Zooming-in on cancer metabolic rewiring with tissue specific constraint-based models , 2016, Comput. Biol. Chem..

[14]  Yusuf A. Hannun,et al.  Biologically active sphingolipids in cancer pathogenesis and treatment , 2004, Nature Reviews Cancer.

[15]  Jeffrey D Orth,et al.  What is flux balance analysis? , 2010, Nature Biotechnology.

[16]  G. Balendiran,et al.  The role of glutathione in cancer , 2004, Cell biochemistry and function.

[17]  Monica L. Mo,et al.  Global reconstruction of the human metabolic network based on genomic and bibliomic data , 2007, Proceedings of the National Academy of Sciences.

[18]  Roded Sharan,et al.  Genome-Scale Metabolic Modeling Elucidates the Role of Proliferative Adaptation in Causing the Warburg Effect , 2011, PLoS Comput. Biol..

[19]  Mark Kester,et al.  Dysregulation of sphingolipid metabolism in cancer , 2011, Cancer biology & therapy.

[20]  O. Reséndis-Antonio,et al.  Modeling Core Metabolism in Cancer Cells: Surveying the Topology Underlying the Warburg Effect , 2010, PloS one.

[21]  Jan Schellenberger,et al.  Use of Randomized Sampling for Analysis of Metabolic Networks* , 2009, Journal of Biological Chemistry.

[22]  J. Locasale Serine, glycine and one-carbon units: cancer metabolism in full circle , 2013, Nature Reviews Cancer.

[23]  R. Weinshilboum,et al.  Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Eytan Ruppin,et al.  Modeling cancer metabolism on a genome scale , 2015, Molecular systems biology.

[25]  J. Gmiński,et al.  Serum total cholesterol and triglycerides levels in patients with lung cancer. , 2000, International journal of molecular medicine.

[26]  J. Menéndez,et al.  Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis , 2007, Nature Reviews Cancer.

[27]  Elmar Heinzle,et al.  Metabolic flux analysis in eukaryotes. , 2010, Current opinion in biotechnology.

[28]  Wei Liu,et al.  The Proline Regulatory Axis and Cancer , 2012, Front. Oncol..

[29]  B. Palsson,et al.  A protocol for generating a high-quality genome-scale metabolic reconstruction , 2010 .

[30]  Natapol Pornputtapong,et al.  Human metabolic atlas: an online resource for human metabolism , 2015, Database J. Biol. Databases Curation.

[31]  Ronan M. T. Fleming,et al.  Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.

[32]  Ying Zhang,et al.  HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..

[33]  I. Nookaew,et al.  Integration of clinical data with a genome-scale metabolic model of the human adipocyte , 2013, Molecular systems biology.

[34]  S. Bertini,et al.  Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. , 2010, Current medicinal chemistry.

[35]  H. Patel,et al.  Significance of Alterations in Plasma Lipid Profile Levels in Breast Cancer , 2008, Integrative cancer therapies.

[36]  Bernhard O. Palsson,et al.  Escher: A Web Application for Building, Sharing, and Embedding Data-Rich Visualizations of Biological Pathways , 2015, PLoS Comput. Biol..

[37]  Mohita Upadhyay,et al.  The Warburg effect: insights from the past decade. , 2013, Pharmacology & therapeutics.

[38]  Marcello Maggiolini,et al.  Glycerophospholipid synthesis as a novel drug target against cancer. , 2011, Current molecular pharmacology.

[39]  Jens Nielsen,et al.  Sampling the Solution Space in Genome-Scale Metabolic Networks Reveals Transcriptional Regulation in Key Enzymes , 2010, PLoS Comput. Biol..